Item 8.01 Other Events.

On August 12, 2021, VYNE Therapeutics Inc. (the "Company") provided an update regarding its liquidity in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Additionally, the Company updated the disclosure in Note 1 of the consolidated financial statements from its Form 10-K for the year ended December 31, 2020 to add disclosure regarding liquidity and capital resources. The Company's independent registered public accounting firm reissued its report on the Company's audited consolidated financial statements as of December 31, 2020 and for the year then ended December 31, 2020 to include an emphasis of matter paragraph regarding liquidity and capital resources as discussed in Note 1 to the consolidated financial statements. The audited consolidated financial statements and the updated report is included as Exhibit 99.1 to this Current Report on Form 8-K. Other than as described in the preceding sentence, Exhibit 99.1 does not revise, modify, update or otherwise affect the audited consolidated financial statements.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

The following exhibit is being filed herewith.





Exhibit No.  Description

  23.1         Consent of PricewaterhouseCoopers LLP

  23.2         Consent of Kesselman & Kesselman

  99.1         Audited Consolidated Financial Statements

             Cover Page Interactive Data File (embedded within the Inline XBRL
104          document)

© Edgar Online, source Glimpses